Osteogenesis Imperfecta: Maintenance of Adult Bone Health - Osteogenesis Imperfecta - page 473

[47] Johnson BE. Review: teriparatide reduces fractures in post-

menopausal women with osteoporosis. Ann Intern Med
2012;157(6):JC3-4.

[50] Lewiecki EM. Sclerostin: a novel target for intervention in the

treatment of osteoporosis. Discov Med 2011;12(65):263-73.

[51] Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC,

Kozloff KM. Sclerostin antibody improves skeletal parameters
in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone
Miner Res 2012;28(1):73-80.

[48] Orwoll E, Veith S, Wang Y, Lapidus J, Keaveny T, Lee D, et al.

Teriparatide improves BMD and bone strength in adults with
osteogenesis imperfecta: a randomized, blinded, placebo con-
trolled trial. Minneapolis, Minnesota, USA: American Society
for Bone and Mineral Research; 2012.

[49] Moester MJ, Papapoulos SE, Löwik CW, van Bezooijen RL.

Sclerostin: current knowledge and future perspectives. Calcif
Tissue Int 2010;87(2):99-107.